Pulse Biosciences, Inc. (FRA:6L8)

Germany flag Germany · Delayed Price · Currency is EUR
12.20
+0.10 (0.83%)
At close: Jan 23, 2026
-33.70%
Market Cap788.86M -25.8%
Revenue (ttm)73.30K
Net Income-63.69M
EPS-0.97
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open12.20
Previous Close12.10
Day's Range12.20 - 12.20
52-Week Range10.80 - 23.60
Betan/a
RSI39.11
Earnings DateMar 27, 2026

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-ena... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2014
Employees 75
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6L8
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements